A major challenge in therapeutic immuno-oncology today is the limited persistence of CAR-T cells. Many studies have focused on altering CAR structure and regulating CAR-T cell differentiation to optimize their clinical efficacy. Research is also focused on identifying new molecular targets to reduce T cell exhaustion. In this white paper, we share an interview with Dr. Verena Brucklacher-Waldert of Revvity, who discusses the epigenetics of T cell exhaustion and practical techniques to assess immune cell epigenetic regulators using CRISPR screens.

A major challenge in therapeutic immuno-oncology today is the limited persistence of CAR-T cells. Many studies have focused on altering CAR structure and regulating CAR-T cell differentiation to optimize their clinical efficacy. Research is also focused on identifying new molecular targets to reduce T cell exhaustion.

In this white paper, we share an interview with Dr. Verena Brucklacher-Waldert of Revvity, who discusses the epigenetics of T cell exhaustion and practical techniques to assess immune cell epigenetic regulators using CRISPR screens.

For research use only. Not for use in diagnostic procedures.